The obese hypertensive: The weight of evidence against β-blockers

Circulation

Volumn 115, Issue 15, 2007, Pages 1973-1974

  Williams, Bryan ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Beta blockers; Blood pressure; Editorials; Hypertension; Obesity

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SIBUTRAMINE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE; BODY FAT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG COST; EDITORIAL; HUMAN; HYPERTENSION; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; APPETITE DEPRESSANTS; COST-BENEFIT ANALYSIS; CYCLOBUTANES; HUMANS; HYPERTENSION; OBESITY; TREATMENT OUTCOME;

EID: 34247277749     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.692970     Document Type: Editorial

References (17)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-1062.
2. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-1610.
3. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Postano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M, Ferrannini E. Visceral fat in hypertension. Hypertension. 2004;44:127-133.
4. Nishina M, Kikuchi T, Yamazaki H, Kameda K, Hiura M, Uchiyama M. Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens Res. 2003;26:281-288.
5. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 206;24:215-233.
6. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250-254.
7. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation. 2007;115:1991-1998.
8. Opie L, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004;22:1453-1458.
9. Mason JM, Dickenson HO, Nicholson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777-1781.
10. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;278:1903-1907.
11. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
12. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
13. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:2131-2141.
14. Dahlof B, Devereaux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm L, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
15. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
16. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
17. NICE/BHS. Clinical guideline 34: hypertension: management of hypertension in adults in primary care: partial update. Available at: http://www.nice.org. uk/CG034guidance. Accessed February 28, 2007.